Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 24, 2008BloodOpen Access

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

View Full Paper
Ask AI
Bookmark
Share

Authors

YOYutaka OkawaHarvard UniversityTHTeru HideshimaBroad InstitutePSPaul M. SteedNovartis (Switzerland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Okawa et al. (2008) studied this question.

synapsesocial.com/papers/6a1c544fea84844e355fbda0https://doi.org/10.1182/blood-2008-04-151928
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Angiogenesis in multiple myeloma2001 · 14 citations
  2. 2Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin2003 · 226 citations
  3. 3Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy2000 · 859 citations
  4. 4The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study2006 · 62 citations
  5. 5SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers2008 · 185 citations